Masimo Corp. fights back against activist shareholder

Trending News 🌧️

Masimo ($NASDAQ:MASI) Corp. is a medical monitoring company that is being sued by an activist shareholder, Politan Capital. In a statement, Masimo said that Politan is refusing to provide information about its significant financial backers and ‘sidecar vehicles’ created for the purpose of launching a campaign against Masimo. Masimo Corp. is fighting back against Politan Capital by filing a counterclaim. In its counterclaim, Masimo is asking for information about Politan’s financial backers and ‘sidecar vehicles.’

Masimo says that it needs this information in order to defend itself against Politan’s campaign. This is an ongoing legal battle between Masimo Corp. and Politan Capital. It remains to be seen who will prevail in this fight.

Stock Price

So far, the news coverage has been mostly negative. However, on Monday, MASIMO CORPORATION stock opened at $137.0 and closed at $136.0, showing that investors are still confident in the company.

VI Analysis

Gorilla companies are those that have achieved stable and high revenue or earning growth due to their strong competitive advantage. MASIMO CORPORATION is classified as a gorilla company based on its VI Star Chart. This means that the company has strong fundamentals that reflect its long-term potential. What type of investors may be interested in such a company?

Investors who are looking for companies with strong growth potential and profitability, but who are not as concerned about dividend yields, may be interested in MASIMO CORPORATION. The company has a high health score of 7/10, which indicates that it is capable of paying off its debt and funding future operations. This makes it an attractive investment option for those looking for a company with strong financials.

VI Peers

In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

– Elekta AB ($OTCPK:EKTAY)

Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

– Essilorluxottica ($LTS:0OMK)

EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

– Compumedics Ltd ($ASX:CMP)

Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.

Summary

Masimo Corporation is a medical technology company that develops, manufactures, and markets various medical devices. The company offers hemodynamic monitoring products, including pulse oximeters and related sensors and software. Masimo’s products are used in a variety of settings, including hospitals, ambulatory surgery centers, and home care. Investors may be interested in Masimo for several reasons.

First, the company has a strong track record of growth. This dominant position gives the company a competitive advantage in terms of both scale and brand recognition. Given its strong growth prospects, market-leading position, and solid financials, Masimo Corporation is a compelling investment opportunity.